Product image of Innohep (Tinzaparin Sodium) supplied by GNH India

Innohep

Active Ingredient:
Tinzaparin Sodium
Origin:
EU

Innohep (Tinzaparin Sodium)

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a 4500 IU/mL injection for subcutaneous use. It is employed to prevent and treat thromboembolic conditions, including deep vein thrombosis, pulmonary embolism, and clot formation in hemodialysis circuits, particularly in surgical or high‑risk patients.

GNH India supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Leo Laboratories Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to manage and prevent venous thromboembolism.

  • Deep vein thrombosis (DVT): prevention of clot formation in surgical patients and treatment of acute DVT.
  • Pulmonary embolism (PE): treatment of acute pulmonary embolism.
  • Hemodialysis circuits: prevention of clot formation during hemodialysis procedures.

How It Works

  • Tinzaparin sodium binds to antithrombin III, enhancing its inhibitory activity against activated factor Xa and, to a lesser extent, thrombin (factor IIa). This acceleration of antithrombin III reduces thrombin generation and fibrin formation, thereby interrupting the coagulation cascade and preventing propagation of existing clots while limiting new clot development. The low molecular weight profile provides a more predictable pharmacokinetic response compared with unfractionated heparin.

Side Effects

Tinzaparin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Injection site reactions: erythema, pain, or bruising at the administration site.
  • Minor bleeding: epistaxis, gum bleeding, or easy bruising.
  • Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

  • Major hemorrhage: life‑threatening internal bleeding.
  • Thrombocytopenia: significant drop in platelet count, including heparin‑induced thrombocytopenia.
  • Allergic reactions: urticaria, angioedema, or anaphylaxis.
  • Spinal/epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

Precautions & Warnings

When prescribing Innohep, clinicians should consider several precautionary measures to minimize risk.

  • Renal impairment: adjust use in patients with severe renal dysfunction.
  • Bleeding risk: avoid in individuals with active bleeding or high hemorrhagic risk.
  • Concomitant anticoagulants: monitor closely when combined with other anticoagulant or antiplatelet agents.
  • Surgery or invasive procedures: discontinue before major surgery to reduce bleeding complications.
  • Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Tinzaparin sodium can interact with several medicines, affecting anticoagulant activity or bleeding risk.

Major Interactions (Avoid)

  • Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk.
  • Thrombolytic agents (e.g., alteplase): synergistic anticoagulant effect leading to severe hemorrhage.

Moderate Interactions (Monitor Closely)

  • Antiplatelet drugs (e.g., aspirin, clopidogrel): enhanced bleeding tendency.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding.
  • Certain antibiotics (e.g., vancomycin): may potentiate anticoagulant effect.
  • Herbal supplements containing ginkgo or garlic: may augment bleeding risk.

Frequently Asked Questions

Innohep is a tinzaparin sodium injection indicated for the prevention of deep vein thrombosis in surgical patients, the treatment of acute deep vein thrombosis, the treatment of pulmonary embolism, and the prevention of clot formation in hemodialysis circuits.

Tinzaparin sodium enhances the activity of antithrombin III, which then more effectively inhibits factor Xa and, to a lesser extent, thrombin (factor IIa). This inhibition reduces thrombin generation and fibrin formation, interrupting the clotting cascade and limiting both existing and new clot development.

The specific dose of Innohep is determined by the prescribing clinician based on the patient’s indication, weight, renal function, and overall risk profile. Dosing regimens are individualized and should follow the prescriber’s instructions and local clinical guidelines.

Safety data for tinzaparin sodium during pregnancy and lactation are limited. It should only be used when the potential maternal benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Innohep, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Innohep (tinzaparin) is a low molecular weight heparin offering more predictable pharmacokinetics and once‑daily subcutaneous dosing compared with unfractionated heparin. Compared with direct oral anticoagulants, it requires injection but provides a reversible anticoagulant effect and is often preferred in patients with renal impairment or those undergoing dialysis.

Innohep should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and sterility.

Innohep is administered by subcutaneous injection, typically into the abdominal wall or thigh. The injection site should be rotated to reduce local irritation, and aseptic technique must be used for each dose.

The most serious risks include major hemorrhage, heparin‑induced thrombocytopenia (HIT), and rare events such as spinal or epidural hematoma. Patients should be monitored for signs of uncontrolled bleeding, sudden drops in platelet count, or neurological symptoms after neuraxial procedures.

Innohep should be avoided in patients with active major bleeding, known hypersensitivity to tinzaparin or other heparins, severe uncontrolled hypertension, or a history of heparin‑induced thrombocytopenia. Caution is also advised for those with severe renal impairment and for pregnant or breastfeeding women unless clearly indicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tinzaparin Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT